Cytokinetics To Move On From Omecamtiv After FDA’s Complete Response Letter
Executive Summary
Company said it will not conduct the additional Phase III trial recommended by the US FDA. Instead, it will focus on its cardiac myosin inhibitor, aficamten, and look for partners to take omecamtiv forward.
You may also be interested in...
Finance Watch: Q4 Venture Financings Slumped But 2024 Outlook Is Optimistic
Private Company Financings: Year-end data from Pitchbook/NVCA, like recent Evaluate numbers, show venture fundraising slid from the third to fourth quarters. However, Taiho increased its VC fund by $100m, Ji Xing closed a $162m series D round and MAPS raised more than $100m.
Cytokinetics Gets A Belated Christmas Present
Aficamten hits nicely in its pivotal hypertrophic cardiomyopathy trial, and a deal will surely follow.
Crunch Time For Cytokinetics As Aficamtem Readout Approaches
The takeover target will present eagerly anticipated Phase III data on the cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy before the end of the year and potential suitors are preparing to pounce, according to the rumor mill.